Obesity dipped slightly in U.S. adults last year, research found — the first time in more than a decade that the country has ...

Nationally representative survey data revealed that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity treatment more than tripled among US adults without diabetes between 2018 ...

Across all BMI categories, GLP-1 RA prescriptions increased significantly during the last 15-year period in a dose-response manner among youth and adults with type 1 diabetes. “Obesity and GLP-1 ...

As sure as the sun rises, prescription medicine use and total drug spending continue to increase in the U.S. To better understand how these trends will play out in the near term, the life sciences ...